Global Genetic Testing Market - Forecast 2026-2032 | AI and Next-Generation Sequencing Drive 14.44% CAGR Toward USD 39.72 Billion
Dublin, Nov. 19, 2026 (GLOBE NEWSWIRE) -- "Genetic Testing Market - Global Forecast 2026-2032" has been added to ResearchAndMarkets.com's offering.
This market research report analyzes the global genetic testing market, which is projected to reach USD 17.60 billion in 2026 and expand at a CAGR of 14.44% to USD 39.72 billion by 2032. It examines the technologies, clinical applications, regulatory developments, and regional dynamics moving genetic testing from specialized diagnostics into mainstream healthcare. The findings support strategic planning, market-entry assessment, and identification of high-growth opportunities across precision medicine.
Market Growth Drivers
Next-generation sequencing, PCR-based assays, microarrays, and targeted panels are enabling earlier disease detection, carrier screening, pharmacogenomics, oncology companion diagnostics, and personalized treatment selection. Declining sequencing costs are also broadening access across hospitals, reference laboratories, and direct-to-consumer channels.
Demand is reinforced by the growing burden of cancer, rare diseases, inherited cardiovascular conditions, reproductive health needs, and medication-response variability. At the same time, regulators, payers, and health systems are placing greater emphasis on analytical and clinical validity, informed consent, data privacy, and equitable access.
Transformative Market Shifts
These insights allow decision-makers to align product portfolios with clinically validated applications while anticipating reimbursement and compliance risks.
Artificial Intelligence in Genetic Testing
Artificial intelligence is improving variant calling, annotation, phenotype matching, laboratory automation, and clinical report generation. AI-enabled bioinformatics can prioritize variants of uncertain significance, connect genomic findings with curated databases such as ClinVar, and accelerate interpretation in oncology and rare disease testing.
Successful deployment requires explainability, validation across diverse populations, bias monitoring, cybersecurity, expert review, and compliance with privacy frameworks including HIPAA and GDPR.
Regional and Economic Group Insights
Coverage of ASEAN, GCC, EU, BRICS, G7, and NATO markets provides a practical basis for comparing regulatory readiness, infrastructure, investment priorities, and partnership potential.
Strategic Priorities for Market Participants
Key Takeaways from This Report
Key Attributes:
Key Topics Covered:
1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. New Revenue Opportunities
3.4. Next-Generation Business Models
3.5. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Market Dynamics
4.3.1. Key Drivers
4.3.2. Key Restraints
4.3.3. Key Opportunities
4.3.4. Key Challenges
4.4. Porter's Five Forces Analysis
4.5. PESTLE Analysis
4.6. Market Outlook
4.6.1. Near-Term Market Outlook (0-2 Years)
4.6.2. Medium-Term Market Outlook (3-5 Years)
4.6.3. Long-Term Market Outlook (5-10 Years)
4.7. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of Artificial Intelligence 2026
7. Genetic Testing Market, by Offering
7.1. Introduction
7.2. Instruments
7.2.1. Sequencers
7.2.2. PCR Systems
7.2.3. Microarray Scanners
7.3. Software & Informatics
7.3.1. Variant interpretation
7.3.2. Clinical decision support
7.3.3. Bioinformatics
7.4. Services
7.4.1. Consulting
7.4.2. Maintenance & Support
7.5. Reagents & Consumables
8. Genetic Testing Market, by Test Type
8.1. Introduction
8.2. Carrier Testing
8.3. Diagnostic Testing
8.4. New Born Screening
8.5. Pharmacogenomics
8.6. Preimplantation Testing
8.7. Prenatal Testing
8.8. Presymptomatic & Predictive Testing
9. Genetic Testing Market, by Technology
9.1. Introduction
9.2. Cytogenetics
9.3. DNA Sequencing
9.4. Gene Expression Profiling
9.5. Microarrays
9.6. Polymerase Chain Reaction (PCR)
10. Genetic Testing Market, by Sample Type
10.1. Introduction
10.2. Blood
10.3. Saliva
10.4. Tissue
10.5. Buccal swab
11. Genetic Testing Market, by Application
11.1. Introduction
11.2. Autoimmune Disorders
11.3. Oncology
11.4. Chronic Diseases
11.5. Genetic Disorders
11.6. Neurodegenerative Diseases
12. Genetic Testing Market, by End-User
12.1. Introduction
12.2. Diagnostic Laboratories
12.3. Home Setting
12.4. Hospitals & Clinics
13. Genetic Testing Market, by Distribution Channel
13.1. Introduction
13.2. Offline
13.3. Online
14. Genetic Testing Market, by Region
14.1. Introduction
14.2. Asia-Pacific
14.3. North America
14.4. Latin America
14.5. Europe
14.6. Middle East
14.7. Africa
15. Genetic Testing Market, by Group
15.1. Introduction
15.2. ASEAN
15.3. GCC
15.4. European Union
15.5. BRICS
15.6. G7
15.7. NATO
16. Genetic Testing Market, by Country
16.1. Introduction
16.2. United States
16.3. Canada
16.4. Mexico
16.5. Brazil
16.6. United Kingdom
16.7. Germany
16.8. France
16.9. Russia
16.10. Italy
16.11. Spain
16.12. China
16.13. India
16.14. Japan
16.15. Australia
16.16. South Korea
17. Competitive Landscape
17.1. Market Share Analysis, 2025
17.2. Market Concentration Analysis, 2025
17.2.1. Concentration Ratio (CR)
17.2.2. Herfindahl Hirschman Index (HHI)
17.3. Recent Developments & Impact Analysis, 2025
17.4. Product Portfolio Analysis, 2025
17.5. Benchmarking Analysis, 2025
18. Company Profiles
18.1. Abbott Laboratories
18.2. Agilent Technologies, Inc.
18.3. Becton, Dickinson and Company
18.4. BGI Genomics
18.5. Bio-Rad Laboratories, Inc.
18.6. Bio-Techne Corporation
18.7. Bruker Corporation
18.8. CooperSurgical Inc.
18.9. Eurofins Scientific SE
18.10. F. Hoffmann-La Roche AG
18.11. GeneDx, LLC
18.12. Guardant Health Inc.
18.13. Illumina, Inc.
18.14. Invitae Corporation
18.15. Laboratory Corporation of America Holdings
18.16. Myriad Genetics, Inc.
18.17. Natera, Inc.
18.18. Newtopia Inc.
18.19. PathogenDx Corporation
18.20. PerkinElmer Inc.
18.21. Qiagen N.V.
18.22. Quest Diagnostics Incorporated
18.23. Revvity Inc.
18.24. Sanofi S.A.
18.25. Sonic Healthcare
18.26. Tempus AI, Inc.
18.27. Thermo Fisher Scientific Inc.
19. Key Experts
List of Figures [25]
List of Tables [380]
For more information about this report visit https://www.researchandmarkets.com/r/bbpqum
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.